Literature DB >> 2426462

Eradication of herpes simplex virus persistence in rat trigeminal ganglia by retrograde axoplasmic transport.

Y Iwasaki, T Yamamoto, H Konno, H Iizuka, H Kudo.   

Abstract

Potential use of retrograde axoplasmic flow to eradicate virus persistence in ganglionic cells was studied in a new herpes simplex virus (HSV) persistence model in rat trigeminal ganglia. After injection of the F strain of HSV type 1 into the mental nerve, viral antigens were detectable in the ganglia by the immunofluorescence and peroxidase methods between postinoculation (p.i.) days 3 and 6 but not thereafter. None of 82 inoculated rats showed signs of acute illness, and some survived for more than 502 days without symptoms. By cocultivation of ganglion tissues with Vero cells, the virus was isolated from 42 of 49 ganglia (85.7%) between 15 and 386 days (p.i.). HSV DNA was solely localized in the nucleus of neurons by immunoperoxidase staining of paraffin sections with a biotinylated HSV DNA probe, and the presence of HSV DNA-positive cells was confirmed in four of four ganglia on p.i. day 6 and in five of six on p.i. day 502. The efficacy of axoplasmic flow in drug delivery to ganglionic cells was investigated by injection of doxorubicin (ADM) into the nerve once used for virus inoculation. As early as 19 h after injection, strong ADM-specific autofluorescence was seen in the nuclei of neurons parental to the mental nerve and in those of adjacent Schwann cells, and the death of ADM-positive cells subsequently ensued. A single injection of ADM reduced the virus isolation rate from 31/37 (84%) to 3/37 (8%).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2426462      PMCID: PMC253072     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

Review 1.  Latent herpes simplex virus and the nervous system,.

Authors:  J G Stevens
Journal:  Curr Top Microbiol Immunol       Date:  1975       Impact factor: 4.291

Review 2.  Herpes simplex virus infection of nervous tissue in animals and man.

Authors:  J R Baringer
Journal:  Prog Med Virol       Date:  1975

3.  The Axis-Cylinders of Peripheral Nerves as Portals of Entry to the Central Nervous System for the Virus of Herpes Simplex in Experimentally Infected Rabbits.

Authors:  E W Goodpasture
Journal:  Am J Pathol       Date:  1925-01       Impact factor: 4.307

4.  Cells that constitutively express the herpes simplex virus immediate-early protein ICP4 allow efficient activation of viral delayed-early genes in trans.

Authors:  R H Persson; S Bacchetti; J R Smiley
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

5.  Somatotopic organization of the trigeminal ganglion in the rat.

Authors:  J M Gregg; A D Dixon
Journal:  Arch Oral Biol       Date:  1973-04       Impact factor: 2.633

6.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

7.  Retrograde axoplasmic transport of toxic lectins is useful for transganglionic tracings of the peripheral nerve.

Authors:  T Yamamoto; Y Iwasaki; H Konno
Journal:  Brain Res       Date:  1983-09-12       Impact factor: 3.252

8.  Role of antibody in primary and recurrent herpes simplex virus infection.

Authors:  A Simmons; A A Nash
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

9.  Spread of virus and distribution of latent infection following ocular herpes simplex in the non-immune and immune mouse.

Authors:  A B Tullo; C Shimeld; W A Blyth; T J Hill; D L Easty
Journal:  J Gen Virol       Date:  1982-11       Impact factor: 3.891

10.  Route of infection, systemic host resistance, and integrity of ganglionic axons influence acute and latent herpes simplex virus infection of the superior cervical ganglion.

Authors:  R W Price; J Schmitz
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.